🔴 Adaptive Biotechnologies Corp is trading 7.2% down today after business separation and $250M convertible notes offering

Adaptive Biotechnologies Corp is trading 7.2% down at $16.20 in pre-market trading after announcing a strategic business separation and a $250 million convertible senior notes offering.

• The company plans to split its MRD and Immune Medicine businesses into two separate operations to optimize strategic focus and operational efficiency.
• The $250 million convertible notes offering is intended to bolster financial flexibility, though it introduces potential dilution risk for current shareholders.
• Investors are reacting to the combined impact of the structural reorganization and the immediate capital raise, which has created short-term strategic uncertainty.